How Much Downside Is Left In Liquidia Stock?

Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% on September 30 after a federal judge ruled that Yutrepia, Liquidia's inhaled lung drug, infringes a United Therapeutics patent. Liquidia subsequently settled all pending litigation with United Therapeutics on October 13, stating that Yutrepia will remain available to patients with PAH without disruption. If the wider market sells off from here, how mu